Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair.

Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB.

Cancer Cell. 2019 May 13;35(5):816. doi: 10.1016/j.ccell.2019.04.011. No abstract available.

PMID:
31085179
2.

Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair.

Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB.

Cancer Cell. 2019 Mar 18;35(3):504-518.e7. doi: 10.1016/j.ccell.2019.01.020. Epub 2019 Feb 28. Erratum in: Cancer Cell. 2019 May 13;35(5):816.

PMID:
30827889
3.

Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.

Leroy E, Balligand T, Pecquet C, Mouton C, Colau D, Shiau AK, Dusa A, Constantinescu SN.

J Allergy Clin Immunol. 2019 Jul;144(1):224-235. doi: 10.1016/j.jaci.2018.12.1023. Epub 2019 Jan 29.

PMID:
30707971
4.

CFI-400945 is not a selective cellular PLK4 inhibitor.

Oegema K, Davis RL, Lara-Gonzalez P, Desai A, Shiau AK.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10808-E10809. doi: 10.1073/pnas.1813310115. Epub 2018 Oct 30. No abstract available.

5.

Phenotypic Screening for Inhibitors of a Mutant Thrombopoietin Receptor.

Ngo A, Koay A, Pecquet C, Diaconu CC, Jenkins DA, Shiau AK, Constantinescu SN, Choong ML.

Methods Mol Biol. 2018;1787:53-66. doi: 10.1007/978-1-4939-7847-2_4.

PMID:
29736709
6.

Identification of H3K4me1-associated proteins at mammalian enhancers.

Local A, Huang H, Albuquerque CP, Singh N, Lee AY, Wang W, Wang C, Hsia JE, Shiau AK, Ge K, Corbett KD, Wang D, Zhou H, Ren B.

Nat Genet. 2018 Jan;50(1):73-82. doi: 10.1038/s41588-017-0015-6. Epub 2017 Dec 18.

7.

Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.

Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel PS, Cavenee WK, Furnari FB.

Genes Dev. 2017 Jun 15;31(12):1212-1227. doi: 10.1101/gad.300079.117. Epub 2017 Jul 19.

8.

mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT.

Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, Guan KL, Mischel PS.

Mol Cell. 2017 Jul 6;67(1):128-138.e7. doi: 10.1016/j.molcel.2017.05.030. Epub 2017 Jun 22.

9.

An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.

Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, Jenkins D, Martini M, Armando AM, Quehenberger O, Cloughesy TF, Furnari FB, Cavenee WK, Tontonoz P, Gahman TC, Shiau AK, Cravatt BF, Mischel PS.

Cancer Cell. 2016 Nov 14;30(5):683-693. doi: 10.1016/j.ccell.2016.09.008. Epub 2016 Oct 13.

10.

GOLPH3 drives cell migration by promoting Golgi reorientation and directional trafficking to the leading edge.

Xing M, Peterman MC, Davis RL, Oegema K, Shiau AK, Field SJ.

Mol Biol Cell. 2016 Dec 1;27(24):3828-3840. Epub 2016 Oct 5.

11.

53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration.

Meitinger F, Anzola JV, Kaulich M, Richardson A, Stender JD, Benner C, Glass CK, Dowdy SF, Desai A, Shiau AK, Oegema K.

J Cell Biol. 2016 Jul 18;214(2):155-66. doi: 10.1083/jcb.201604081.

12.

Chemical regulators of epithelial plasticity reveal a nuclear receptor pathway controlling myofibroblast differentiation.

Carthy JM, Stöter M, Bellomo C, Vanlandewijck M, Heldin A, Morén A, Kardassis D, Gahman TC, Shiau AK, Bickle M, Zerial M, Heldin CH, Moustakas A.

Sci Rep. 2016 Jul 19;6:29868. doi: 10.1038/srep29868.

13.

Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.

Leroy E, Dusa A, Colau D, Motamedi A, Cahu X, Mouton C, Huang LJ, Shiau AK, Constantinescu SN.

Biochem J. 2016 Jun 1;473(11):1579-91. doi: 10.1042/BCJ20160085. Epub 2016 Mar 30.

14.

Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.

Tögel L, Nightingale R, Chueh AC, Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D, Dhillon AS, Dawson MA, Diez-Dacal B, Gahman TC, Filippakopoulos P, Shiau AK, Mariadason JM.

Mol Cancer Ther. 2016 Jun;15(6):1217-26. doi: 10.1158/1535-7163.MCT-15-0724. Epub 2016 Mar 16.

15.

A Cell Biologist's Field Guide to Aurora Kinase Inhibitors.

de Groot CO, Hsia JE, Anzola JV, Motamedi A, Yoon M, Wong YL, Jenkins D, Lee HJ, Martinez MB, Davis RL, Gahman TC, Desai A, Shiau AK.

Front Oncol. 2015 Dec 21;5:285. doi: 10.3389/fonc.2015.00285. eCollection 2015.

16.

EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.

Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, Barr CL, Furnari FB, Cloughesy TF, Yong WH, Gahman TC, Shiau AK, Cavenee WK, Ren B, Mischel PS.

Mol Cell. 2015 Oct 15;60(2):307-18. doi: 10.1016/j.molcel.2015.09.002. Epub 2015 Oct 8.

17.

Natural Loss of Mps1 Kinase in Nematodes Uncovers a Role for Polo-like Kinase 1 in Spindle Checkpoint Initiation.

Espeut J, Lara-Gonzalez P, Sassine M, Shiau AK, Desai A, Abrieu A.

Cell Rep. 2015 Jul 7;12(1):58-65. doi: 10.1016/j.celrep.2015.05.039. Epub 2015 Jun 25.

18.

Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4.

Wong YL, Anzola JV, Davis RL, Yoon M, Motamedi A, Kroll A, Seo CP, Hsia JE, Kim SK, Mitchell JW, Mitchell BJ, Desai A, Gahman TC, Shiau AK, Oegema K.

Science. 2015 Jun 5;348(6239):1155-60. doi: 10.1126/science.aaa5111. Epub 2015 Apr 30.

19.

Common regulatory control of CTP synthase enzyme activity and filament formation.

Noree C, Monfort E, Shiau AK, Wilhelm JE.

Mol Biol Cell. 2014 Aug 1;25(15):2282-90. doi: 10.1091/mbc.E14-04-0912. Epub 2014 Jun 11.

20.

Direct binding of SAS-6 to ZYG-1 recruits SAS-6 to the mother centriole for cartwheel assembly.

Lettman MM, Wong YL, Viscardi V, Niessen S, Chen SH, Shiau AK, Zhou H, Desai A, Oegema K.

Dev Cell. 2013 May 13;25(3):284-98. doi: 10.1016/j.devcel.2013.03.011.

21.

Discovery and optimization of a series of liver X receptor antagonists.

Jiao X, Kopecky DJ, Fisher B, Piper DE, Labelle M, McKendry S, Harrison M, Jones S, Jaen J, Shiau AK, Escaron P, Danao J, Chai A, Coward P, Kayser F.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5966-70. doi: 10.1016/j.bmcl.2012.07.048. Epub 2012 Jul 21.

PMID:
22901900
22.

Discovery of a new binding mode for a series of liver X receptor agonists.

Kopecky DJ, Jiao XY, Fisher B, McKendry S, Labelle M, Piper DE, Coward P, Shiau AK, Escaron P, Danao J, Chai A, Jaen J, Kayser F.

Bioorg Med Chem Lett. 2012 Apr 1;22(7):2407-10. doi: 10.1016/j.bmcl.2012.02.028. Epub 2012 Feb 20.

PMID:
22406115
23.

Heteroaromatic-aminomethyl quinolones: potent and selective iNOS inhibitors.

Durón SG, Lindstrom A, Bonnefous C, Zhang H, Chen X, Symons KT, Sablad M, Rozenkrants N, Zhang Y, Wang L, Yazdani N, Shiau AK, Noble SA, Rix P, Rao TS, Hassig CA, Smith ND.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1237-41. doi: 10.1016/j.bmcl.2011.11.073. Epub 2011 Nov 25.

PMID:
22182498
24.

Identification and SAR of selective inducible nitric oxide synthase (iNOS) dimerization inhibitors.

Gahman TC, Herbert MR, Lang H, Thayer A, Symons KT, Nguyen PM, Massari ME, Dozier S, Zhang Y, Sablad M, Rao TS, Noble SA, Shiau AK, Hassig CA.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6888-94. doi: 10.1016/j.bmcl.2011.08.112. Epub 2011 Sep 8.

PMID:
21986586
25.

Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases.

Symons KT, Nguyen PM, Massari ME, Anzola JV, Staszewski LM, Wang L, Yazdani N, Dorow S, Muhammad J, Sablad M, Rozenkrants N, Bonefous C, Payne JE, Rix PJ, Shiau AK, Noble SA, Smith ND, Hassig CA, Zhang Y, Rao TS.

J Pharmacol Exp Ther. 2011 Feb;336(2):468-78. doi: 10.1124/jpet.110.172817. Epub 2010 Oct 29.

PMID:
21036913
26.
27.

Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.

Herbert MR, Siegel DL, Staszewski L, Cayanan C, Banerjee U, Dhamija S, Anderson J, Fan A, Wang L, Rix P, Shiau AK, Rao TS, Noble SA, Heyman RA, Bischoff E, Guha M, Kabakibi A, Pinkerton AB.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5718-21. doi: 10.1016/j.bmcl.2010.08.014. Epub 2010 Aug 10.

PMID:
20801037
28.

Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma.

Davis RL, Kahraman M, Prins TJ, Beaver Y, Cook TG, Cramp J, Cayanan CS, Gardiner EM, McLaughlin MA, Clark AF, Hellberg MR, Shiau AK, Noble SA, Borchardt AJ.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3361-6. doi: 10.1016/j.bmcl.2010.04.020. Epub 2010 Apr 11.

PMID:
20434334
29.

Water-soluble PDE4 inhibitors for the treatment of dry eye.

Govek SP, Oshiro G, Anzola JV, Beauregard C, Chen J, Coyle AR, Gamache DA, Hellberg MR, Hsien JN, Lerch JM, Liao JC, Malecha JW, Staszewski LM, Thomas DJ, Yanni JM, Noble SA, Shiau AK.

Bioorg Med Chem Lett. 2010 May 1;20(9):2928-32. doi: 10.1016/j.bmcl.2010.03.023. Epub 2010 Mar 7.

PMID:
20378348
30.

Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models.

Bonnefous C, Payne JE, Roppe J, Zhuang H, Chen X, Symons KT, Nguyen PM, Sablad M, Rozenkrants N, Zhang Y, Wang L, Severance D, Walsh JP, Yazdani N, Shiau AK, Noble SA, Rix P, Rao TS, Hassig CA, Smith ND.

J Med Chem. 2009 May 14;52(9):3047-62. doi: 10.1021/jm900173b.

PMID:
19374401
31.

KLYP956 is a non-imidazole-based orally active inhibitor of nitric-oxide synthase dimerization.

Symons KT, Massari ME, Nguyen PM, Lee TT, Roppe J, Bonnefous C, Payne JE, Smith ND, Noble SA, Sablad M, Rozenkrants N, Zhang Y, Rao TS, Shiau AK, Hassig CA.

Mol Pharmacol. 2009 Jul;76(1):153-62. doi: 10.1124/mol.109.055434. Epub 2009 Apr 13.

PMID:
19364813
32.

Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.

Payne JE, Bonnefous C, Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Hoffman TZ, Rao TS, Shiau AK, Malecha JW, Noble SA, Hager JH, Smith ND.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6093-6. doi: 10.1016/j.bmcl.2008.10.029. Epub 2008 Oct 11.

PMID:
18954983
33.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.

Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Payne JE, Jenkins DA, Bonnefous C, Trotter C, Wang Y, Anzola JV, Milkova EL, Hoffman TZ, Dozier SJ, Wiley BM, Saven A, Malecha JW, Davis RL, Muhammad J, Shiau AK, Noble SA, Rao TS, Smith ND, Hager JH.

Mol Cancer Ther. 2008 May;7(5):1054-65. doi: 10.1158/1535-7163.MCT-07-2347.

34.

Back to basics: label-free technologies for small molecule screening.

Shiau AK, Massari ME, Ozbal CC.

Comb Chem High Throughput Screen. 2008 Mar;11(3):231-7. Review.

PMID:
18336215
35.

Inhibition of inducible nitric oxide synthase expression by a novel small molecule activator of the unfolded protein response.

Symons KT, Massari ME, Dozier SJ, Nguyen PM, Jenkins D, Herbert M, Gahman TC, Noble SA, Rozenkrants N, Zhang Y, Rao TS, Shiau AK, Hassig CA.

Curr Chem Genomics. 2008 Sep 27;2:1-9. doi: 10.2174/1875397300802010001.

36.

Synthesis and SAR of thiophene containing kinesin spindle protein (KSP) inhibitors.

Pinkerton AB, Lee TT, Hoffman TZ, Wang Y, Kahraman M, Cook TG, Severance D, Gahman TC, Noble SA, Shiau AK, Davis RL.

Bioorg Med Chem Lett. 2007 Jul 1;17(13):3562-9. Epub 2007 Apr 29.

PMID:
17498954
37.

Structural Analysis of E. coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements.

Shiau AK, Harris SF, Southworth DR, Agard DA.

Cell. 2006 Oct 20;127(2):329-40.

39.

A structural explanation for ERalpha/ERbeta SERM discrimination.

Greene GL, Shiau AK, Nettles KW.

Ernst Schering Res Found Workshop. 2004;(46):33-45. Review.

PMID:
15248503
40.

Orphan nuclear receptors: from new ligand discovery technologies to novel signaling pathways.

Shiau AK, Coward P, Schwarz M, Lehmann JM.

Curr Opin Drug Discov Devel. 2001 Sep;4(5):575-90. Review.

PMID:
12825453
41.

Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism.

Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL.

Nat Struct Biol. 2002 May;9(5):359-64.

PMID:
11953755
42.

Hormone selectivity in thyroid hormone receptors.

Wagner RL, Huber BR, Shiau AK, Kelly A, Cunha Lima ST, Scanlan TS, Apriletti JW, Baxter JD, West BL, Fletterick RJ.

Mol Endocrinol. 2001 Mar;15(3):398-410.

PMID:
11222741
43.

Estrogen receptor pathways to AP-1.

Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):311-7. Review.

PMID:
11162939
44.

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL.

Cell. 1998 Dec 23;95(7):927-37.

45.

Pro region C-terminus:protease active site interactions are critical in catalyzing the folding of alpha-lytic protease.

Peters RJ, Shiau AK, Sohl JL, Anderson DE, Tang G, Silen JL, Agard DA.

Biochemistry. 1998 Sep 1;37(35):12058-67.

PMID:
9724517
46.

Inhibition of alpha-lytic protease by pro region C-terminal steric occlusion of the active site.

Sohl JL, Shiau AK, Rader SD, Wilk BJ, Agard DA.

Biochemistry. 1997 Apr 1;36(13):3894-902.

PMID:
9092819
47.

Determinants of performance in the isocitrate dehydrogenase of Escherichia coli.

Dean AM, Shiau AK, Koshland DE Jr.

Protein Sci. 1996 Feb;5(2):341-7.

48.

P2U purinoceptors: cDNA cloning, signal transduction mechanisms and structure-function analysis.

Lustig KD, Weisman GA, Turner JT, Garrad R, Shiau AK, Erb L.

Ciba Found Symp. 1996;198:193-204; discussion 204-7. Review.

PMID:
8879826
49.

A phage display system for studying the sequence determinants of protein folding.

Gu H, Yi Q, Bray ST, Riddle DS, Shiau AK, Baker D.

Protein Sci. 1995 Jun;4(6):1108-17.

50.

The role of pro regions in protein folding.

Baker D, Shiau AK, Agard DA.

Curr Opin Cell Biol. 1993 Dec;5(6):966-70. Review.

PMID:
8129949

Supplemental Content

Loading ...
Support Center